% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • no2sound no2sound Feb 28, 2009 10:29 AM Flag

    Zack - Isis Pharma Maintains a Buy

    Isis Pharma Maintains a Buy

    Posted Fri Feb 27, 10:37 am ET
    Posted By: Jason Napodano, CFA

    We are reiterating or rating on Isis Pharmaceuticals (ISIS) of a Buy and maintaining our price target of $22.

    We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases. In our view, antisense as a platform is today where biologics were 10 years ago.

    The company's leading candidates are mipomersen (w/ Genzyme, GENZ) for high cholesterol and ISIS-113715 for diabetes, along with several other proprietary and partnered programs for oncology, inflammatory disease, asthma, and viral infections. Our financial model forecasts sustained profitability in 2011.

53.96-0.97(-1.77%)Aug 3 4:00 PMEDT